Q1 2021 Commercial Metrics
April 13, 2021
Commercial Metrics Overview
•
•
Preliminary ZILRETTA® net sales of $24.6 million in Q1 2021
4,417 accounts had purchased ZILRETTA, as of March 31, 2021; up from 4,248, as of December 31, 2020
- 3,470 accounts had re-ordered ZILRETTA (79% of accounts that had purchased), as of March 31, 2021; up from 3,321 accounts that had re-ordered ZILRETTA (78% of accounts that had purchased) as of December 31, 2020
- As of March 31, 2021, Flexion had ~$154 million in cash, cash equivalents and marketable securities and ~49.9 million shares outstanding
2
ZILRETTA Net Sales
Quarterly Since Launch
ZILRETTA Net Sales ($ Millions)
30 | |||||
$26.3 | |||||
25 | $23.7 | $23.7 | $24.6 | ||
$21.8 | |||||
20 | $20.1 | ||||
$17.0 | $15.5 | ||||
15 | |||||
$10.6 | |||||
10 | $9.5 | ||||
$7.0 | |||||
5 | $3.8 | ||||
$2.2 |
$0.4
-
Q4 2017 | Q1 2018 | Q2 2018 | Q3 2018 | Q4 2018 | Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 | Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | Q1 2021 |
Note: Flexion recognizes ZILRETTA sales upon receipt of product by specialty distributors and pharmacies.
3
# of Accounts
Distribution of Accounts by ZILRETTA Purchases
Cumulative
5,000
4,500 | 4,248 | 4,417 | ||||||||||||
4,072 | ||||||||||||||
3,858 | ||||||||||||||
4,000 | 3,672 | |||||||||||||
3,488 | 1,358 | |||||||||||||
3,500 | ||||||||||||||
3,130 | ||||||||||||||
3,000 | 2,733 | |||||||||||||
2,500 | 2,247 | 1,186 | ||||||||||||
2,000 | 1,837 | |||||||||||||
1,500 | 1,434 | |||||||||||||
1,000 | 953 | |||||||||||||
530 | 1,873 | |||||||||||||
500 | ||||||||||||||
115 | ||||||||||||||
0 | ||||||||||||||
Q4 2017 | Q1 2018 | Q2 2018 | Q3 2018 | Q4 2018 | Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 | Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | Q1 2021 | |
Accounts purchased 1-10 units | Accounts purchased 11-50 units | Accounts purchased 51+ units | ||
Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics, and certain medical centers or hospitals) subsequently
purchase ZILRETTA directly from these specialty distributors and the specialty pharmacy.
4
ZILRETTA Units
Distribution of ZILRETTA Purchases by Accounts
Cumulative
398,786
400,000
350,000 | 345,697 | |||||||||||||||||
300,000 | 295,641 | |||||||||||||||||
250,000 | 249,024 | |||||||||||||||||
212,327 | 360,209 | |||||||||||||||||
200,000 | 175,784 | |||||||||||||||||
150,000 | 138,284 | |||||||||||||||||
100,000 | 89,656 | |||||||||||||||||
59,750 | ||||||||||||||||||
50,000 | 23,057 | 39,886 | ||||||||||||||||
4,077 | 10,935 | |||||||||||||||||
459 | 31,170 | |||||||||||||||||
7,407 | ||||||||||||||||||
0 | ||||||||||||||||||
Q4 2017 | Q1 2018 | Q2 2018 | Q3 2018 | Q4 2018 | Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 | Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | Q1 2021 | |||||
Accounts purchased 1-10 units | Accounts purchased 11-50 units | Accounts purchased 51+ units | ||||||||||||||||
Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics, and certain medical centers or hospitals) subsequently
purchase ZILRETTA directly from these specialty distributors and the specialty pharmacy.
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Flexion Therapeutics Inc. published this content on 13 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 April 2021 20:08:06 UTC.